However, it must be noted that the interpretation of the true predictive value of the MGMT promoter methylation status has been limited in both trials, as the analytical performance of the assay was not investigated and MGMT test results were available in only a fraction of cases (56% in the NOA-08 study and 59% in the Nordic Glioma Study, respectively). This evidence concerns the gene MGMT and central nervous system cancer.